Addmedica signs agreement with ProStrakan, taking over all rights to Siklos, a pharmaceutical specialty under development in sickle cell syndromes

Paris, 25 February 2007 -- Addmedica SAS announces today the signature of an agreement with the British Group, PROSTRAKAN, providing for the taking over of all the rights to SIKLOS® (hydroxycarbamide), a pharmaceutical specialty under development in sickle cell syndromes. This indication gave raise to an Orphan Drug Designation within the EU in 2003 and, once approved thought a centralized procedure, SIKLOS® will be available for marketing in the 25 member states of the European Union with a 10-years-market exclusivity.

Sickle cell syndrome is a group of inherited genetic diseases caused by an abnormality of the haemoglobin A, the blood oxygen carrier protein. The abnormality leads to the haemoglobin polymerisation and to changes in the shape and behaviour of the red blood cells. This causes small clots that block the blood flow, and repeated painful vaso-occlusive crises. The clinical picture of patients with sickle cell syndrome can be remarkably different. Some remain virtually without complaints, while others suffer repeated crises requiring admission to hospital. In the long run, this causes severe damages to several organs in the body. This may occur as soon as early childhood, where the mortality reaches a peak between 1 and 3 years of age. Sickle cell syndrome is reported to affect about 22,000 in the European Union.

Up to now, no medicine was registered for the treatment of sickle cell syndrome in Europe. Blood transfusions, oxygen, and pain relieving narcotics help to improve the symptoms of the crisis. Bone marrow transplantation can provide a cure, but it is known to be effective and safe only in selected children.

In patients with sickle cell disease, several studies reported that hydroxycarbamide reduced the frequency of painful vaso-occlusive crises and the need for blood transfusions. Actually, hydroxycarbamide has the ability to reactivate the synthesis of faetal haemoglobin, haemoglobin F, which can compensate for the lack of normal haemoglobin.

ADDMEDICA is a European start-up based in Paris, France, dedicated to adding innovative and personalised therapeutic responses to patients suffering from rare diseases.
"We are very proud to have been recognized as the best partner by the Prostrakan to take over the SIKLOS® development in sickle cell syndromes. This is an important step for ADDMEDICA in accordance with the strategy to focus on niche market and orphan drugs and the willingness to develop our European presence. The market availability of SIKLOS® throughout Europe with adapted galenical forms represent a great hope for adults and children suffering from this rare disease", said François Anger, chairman of ADDMEDICA.

For more information, please contact:

ADDMEDICA
84 rue Amsterdam F-75009 Paris
Phone +33 (0) 172 69 01 86
Fax +33 (0) 173 72 94 13
http://www.addmedica.com

François ANGER, Legal and Finances
Bernard DAUVERGNE, Medical and Marketing
Jean-Michel DERIPPE, Supply chain

SOURCE: ADDMEDICA

To read more Press Release articles, click here.